This week the PSA test is in the media spotlight after results from a large prostate cancer trial were released. So what should men do if they are worried about prostate cancer? Who should have a PSA test? Our Specialist Nurse, Ali Rooke sets out the facts.
This weekend, national media picked up a story that we reported in November about an NHS England scheme trialling a “one-stop-shop” process for diagnosing prostate cancer. The story was picked up from The Daily Mail, who have recently begun a prostate cancer campaign after being moved by our news that prostate cancer is now the third biggest cancer killer.
After we investigated complaints from men unable to get hold of the off-patent prostate cancer drug, bicalutamide, the British Generic Manufacturers' Association has told us problems with supply shouldn't last long.
BLOG: BLOG: When a successful clinical trial of a new treatment is reported, what happens next? Even the most exciting new methods still have a long way to go before doctors can prescribe them. Behind the scenes, we work to try and make sure these treatments get to the men who need them. This month, Policy Manager, Tim Windle, is in the thick of it in a bid to get a combination therapy for advanced disease approved.
Results of a report released today have shown that the average time it takes for a man to receive a diagnosis of prostate cancer in England is 56 days following referral – far longer than the 28 day target that health officials are working towards and the average 14 day diagnosis period for breast cancer. We look into the reasons behind this dramatic difference and what is being done about it.
At a conference in London this week, Secretary of State for Health, Jeremy Hunt, announced plans to increase the number of specialists employed by the NHS to improve cancer diagnosis and care. But despite this welcome news, some important staffing shortfalls still need to be addressed.
A report released by the Royal College of Surgeons shows more men are getting an appropriate level of treatment, but issues with late diagnosis persist and uptake of mpMRI has been patchy. However, a pilot scheme also announced today offers a promising step forward.
Plans to rollout mpMRI scans before a first biopsy for all UK men suspected of prostate cancer are under threat, as long-term vacancies and increasing demand put a strain on the NHS's radiology services.
Prostate Cancer UK welcomes new data from the STAMPEDE trial that clarifies there is no difference in the benefits offered by both treatments for men newly diagnosed with advanced disease, but now we want the option of earlier abiraterone made available to all men.
Prostate Cancer UK is urging health authorities to improve access to prostatectomy treatment for men in Northern Ireland, after reports of delays and inadequate support for patients being flown to England for surgery.